DK2254591T3 - Inhibering eller behandling af gastrointestinal biofilm - Google Patents

Inhibering eller behandling af gastrointestinal biofilm

Info

Publication number
DK2254591T3
DK2254591T3 DK09709038.5T DK09709038T DK2254591T3 DK 2254591 T3 DK2254591 T3 DK 2254591T3 DK 09709038 T DK09709038 T DK 09709038T DK 2254591 T3 DK2254591 T3 DK 2254591T3
Authority
DK
Denmark
Prior art keywords
inhibition
treatment
gastrointestinal biofilm
biofilm
gastrointestinal
Prior art date
Application number
DK09709038.5T
Other languages
English (en)
Inventor
Stephen F Olmstead
Original Assignee
Prothera Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prothera Inc filed Critical Prothera Inc
Application granted granted Critical
Publication of DK2254591T3 publication Critical patent/DK2254591T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18—Testing for antimicrobial activity of a material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
DK09709038.5T 2008-02-08 2009-02-09 Inhibering eller behandling af gastrointestinal biofilm DK2254591T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6518608P 2008-02-08 2008-02-08
PCT/US2009/033599 WO2009100456A2 (en) 2008-02-08 2009-02-09 Inhibition and treatment of gastrointestinal biofilms

Publications (1)

Publication Number Publication Date
DK2254591T3 true DK2254591T3 (da) 2017-11-06

Family

ID=40939056

Family Applications (1)

Application Number Title Priority Date Filing Date
DK09709038.5T DK2254591T3 (da) 2008-02-08 2009-02-09 Inhibering eller behandling af gastrointestinal biofilm

Country Status (10)

Country Link
US (3) US20090202516A1 (da)
EP (1) EP2254591B1 (da)
JP (2) JP6047273B2 (da)
CA (1) CA2715266A1 (da)
DK (1) DK2254591T3 (da)
ES (1) ES2645062T3 (da)
NO (1) NO2254591T3 (da)
PL (1) PL2254591T3 (da)
PT (1) PT2254591T (da)
WO (1) WO2009100456A2 (da)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101801521B (zh) 2007-05-14 2015-06-17 纽约州立大学研究基金会 生物膜中细菌细胞内的生理学分散响应诱导
US8617542B2 (en) * 2008-04-03 2013-12-31 Kane Biotech Inc. DispersinB™, 5-fluorouracil, deoxyribonuclease I and proteinase K-based antibiofilm compositions and uses thereof
US20110091606A1 (en) * 2009-09-23 2011-04-21 Todd Ehrlich Dietary Supplements in Beverages or Other Forms, and Methods of Use and Production
WO2011063394A2 (en) * 2009-11-23 2011-05-26 Olmstead Stephen F Compositions and methods comprising serratia peptidase for inhibition and treatment of biofilms related to certain conditions
US9011909B2 (en) 2010-09-03 2015-04-21 Wisconsin Pharmacal Company, Llc Prebiotic suppositories
US20120070423A1 (en) * 2010-09-21 2012-03-22 Puneet Nanda Oral composition and method of forming and using same
US9198957B2 (en) 2011-01-31 2015-12-01 The Trustees Of Columbia University In The City Of New York Treatment and prevention of bacterial vaginosis and Gardnerella vaginalis infections
WO2012118535A1 (en) 2011-03-01 2012-09-07 Quorum Innovations, Llc Materials and methods for treating conditions associated with pathogenic biofilm
US10420822B2 (en) 2011-06-13 2019-09-24 Ziolase, Llc Compositions and methods to prevent and treat biofilms
US20120315260A1 (en) * 2011-06-13 2012-12-13 Svetlana A. Ivanova Compositions and Methods to Prevent and Treat Biofilms
GB201208879D0 (en) 2012-05-21 2012-07-04 London School Hygiene & Tropical Medicine Therapeutic for treating Clostridium difficile infection
WO2014130007A1 (en) * 2013-02-19 2014-08-28 Deerland Enzymes, Inc. Proteolytic compositions for rapidly and extensively degrading protein supplements
WO2017211737A1 (fr) * 2016-06-08 2017-12-14 Onelife S.A. Composition comprenant au moins une enzyme et au moins une molécule microbicide pour la prévention ou le traitement des infections post-implantatoires
JP7189899B2 (ja) * 2017-03-10 2022-12-14 バイオーム ヘルス エルエルシー 哺乳動物において健康な微生物フローラを促進するための組成物および方法
CN108359696A (zh) * 2018-02-28 2018-08-03 苏州昆蓝生物科技有限公司 一种低聚木糖的制备方法
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
CN118252181A (zh) * 2024-05-30 2024-06-28 中国农业科学院北京畜牧兽医研究所 一种用于杀灭沙门氏菌的复合酶系及其应用
CN120093994A (zh) * 2025-03-07 2025-06-06 大连医科大学 一种纤维素酶在降解细菌生物膜中的应用

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4994390A (en) * 1989-03-13 1991-02-19 Nalco Chemical Company Enzyme blend containing cellulase to control industrial slime
US5389369A (en) * 1991-02-21 1995-02-14 Exoxemis, Inc. Halo peroxidase containing compositions for killing yeast and sporular microorganisms
US5260074A (en) * 1992-06-22 1993-11-09 Digestive Care Inc. Compositions of digestive enzymes and salts of bile acids and process for preparation thereof
US5861271A (en) * 1993-12-17 1999-01-19 Fowler; Timothy Cellulase enzymes and systems for their expressions
US5436003A (en) * 1994-02-10 1995-07-25 Triarco Industries, Inc. Method of alleviating gastrointestinal distress with a composition containing beta-fructofuransidase, cellulase and hemi-cellulase
GB9409336D0 (en) * 1994-05-10 1994-06-29 Finnfeeds Int Ltd Use of an enzyme for manufacturing an agent for the treatment and/or prophylaxis of coccidiosis
WO1996023062A1 (en) * 1995-01-26 1996-08-01 Novo Nordisk A/S Animal feed additives comprising xylanase
KR19980703611A (ko) 1995-04-07 1998-12-05 리씨알렉산더디 엑소폴리사카라이드 분해 효소 및 이의 용도
US6365208B1 (en) * 1995-06-29 2002-04-02 Mcneil-Ppc, Inc. Stable lactase tablets
EP0862371B1 (en) * 1995-11-06 2002-05-08 Novozymes A/S Use of galactanase in animal feed
US6599714B1 (en) 1996-03-13 2003-07-29 University Technologies International Inc. Method of growing and analyzing a biofilm
US6100080A (en) * 1996-12-18 2000-08-08 Novo Nordisk A/S Method for enzymatic treatment of biofilm
GB2327345B (en) * 1997-07-18 1999-06-23 Finnfeeds Int Ltd Use of an enzyme for manufacturing an agent for controlling bacterial infection
ATE287895T1 (de) * 1997-08-08 2005-02-15 Aventis Pharma Gmbh Substituierte tetrahydropyranderivate sowie verfahren zu deren herstellung
US6759040B1 (en) * 1997-09-12 2004-07-06 University Of Maryland, College Park Preparation and use of biofilm-degrading, multiple-specificity, hydrolytic enzyme mixtures
US20020037260A1 (en) * 1997-10-16 2002-03-28 Budny John A. Compositions for treating biofilm
US6830745B1 (en) * 1997-10-16 2004-12-14 Pharmacal Biotechnologies, Llc Compositions for treating biofilm
ITMI981148A1 (it) 1998-05-22 1999-11-22 Therapicon Srl Utilizzo di lisozima c modificato per preparare composizioni medicinali per il trattamento di alcune gravi malattie
DE69942777D1 (de) * 1998-07-28 2010-10-28 Takeda Pharmaceutical Leicht zerfallende feste Zubereitung
JP2000226335A (ja) * 1998-12-04 2000-08-15 Amano Pharmaceut Co Ltd 経口用酵素製剤、酵素含有食材及び酵素製剤の服用方法
US7153503B1 (en) * 1998-12-19 2006-12-26 Janeel Henderson Comprehensive dietary supplement
EP1068871A1 (en) * 1999-07-07 2001-01-17 Jean-Paul Perraudin Novel methods and medicament for treating infections diseases involving microbial biofilms
CA2284103A1 (en) * 1999-09-30 2001-03-30 Edith Bonnelye Estrogen related receptor, err.alpha., a regulator of bone formation
UA78486C2 (uk) * 1999-12-10 2007-04-10 Хемджен Корпорейшн Композиція для перорального введення птахам та тваринам для лікування або зниження ризику інфекції травного тракту (варіанти), її застосування (варіанти) та спосіб лікування або зниження ризику інфекцій травного тракту (варіанти)
IL133851A (en) 1999-12-31 2002-12-01 Smoler Feed Additives And Tech Dietary supplement for animals
US6855548B2 (en) * 2000-02-08 2005-02-15 F. Hoffman-La Roche Ag Use of acid-stable proteases in animal feed
JP2001325067A (ja) 2000-05-17 2001-11-22 Ricoh Co Ltd 筆記情報処理装置と筆記情報処理システム及び情報記録媒体
US20040170617A1 (en) * 2000-06-05 2004-09-02 Finegold Sydney M. Method of treating diseases associated with abnormal gastrointestinal flora
US20040062757A1 (en) * 2001-06-05 2004-04-01 Finegold Sydney M. Method of testing gastrointestinal diseases associated with species of genus clostridium
US20020013270A1 (en) 2000-06-05 2002-01-31 Bolte Ellen R. Method for treating a mental disorder
WO2001098214A1 (en) * 2000-06-19 2001-12-27 Novozymes Biotech, Inc. Methods for eliminating the formation of biofilm
US6716813B2 (en) 2000-11-28 2004-04-06 House Ear Institute Use of antimicrobial proteins and peptides for the treatment of otitis media and paranasal sinusitis
CA2442685A1 (en) * 2001-04-04 2002-10-17 Edith Bonnelye Estrogen receptor-related receptor alpha (err.alpha.) and cartilage formation
AU2002307448A1 (en) * 2001-04-20 2002-11-05 President And Fellows Of Harvard College Methods and compositions for the modulation of biofilm formation
US20030099626A1 (en) * 2001-11-20 2003-05-29 Health Education Corporation Nutrient absorption enhancing compositions and methods
US8541472B2 (en) * 2001-12-05 2013-09-24 Aseptica, Inc. Antiseptic compositions, methods and systems
AU2002364491A1 (en) * 2002-01-03 2003-07-30 Yissum Research Development Company Of The Hebrew University Of Jerusalem Edible compositions capable of removing oral biofilm
US7572439B2 (en) * 2002-03-26 2009-08-11 Biosynexus Incorporated Enzyme disruption of bacterial biofilms
BR0304221A (pt) * 2002-04-05 2004-07-27 Novozymes North America Inc Método para melhorar a resistência a abrasão e/ou força de tração de um material celulósico acabado em prensa durável, composição para tratar materiais celulósicos
US20040005304A1 (en) * 2002-07-08 2004-01-08 Mak Wood, Inc. Novel compositions and methods for treating neurological disorders and associated gastrointestinal conditions
DE10237317B4 (de) * 2002-08-15 2010-04-08 3M Espe Ag Enzymhaltige Zusammensetzung, Verfahren zu deren Herstellung und deren Verwendung
US6900173B2 (en) * 2002-09-11 2005-05-31 Kenneth A. Martin Perioperative multivitamin protein bar for use in preparing an individual for fast surgical recovery
US20050079594A1 (en) * 2002-10-31 2005-04-14 Karine Marion Method of removing a biofilm
JP5073169B2 (ja) * 2002-12-20 2012-11-14 ユニバーシティー オブ メディシン アンド デンティストリー オブ ニュージャージー 細菌性および真菌性生物膜の酵素による剥離のための組成物および方法
WO2004066945A2 (en) * 2003-01-24 2004-08-12 Diversa Corporation Enzymes and the nucleic acids encoding them and methods for making and using them
US6692726B1 (en) * 2003-02-11 2004-02-17 Colgate Palmolive Company Enzyme containing oral composition having enhanced stability
US7067124B2 (en) * 2003-03-28 2006-06-27 National Enzyme Company Protease composition and method for treating a digestive disorder
US7700544B2 (en) * 2003-06-12 2010-04-20 Queens's University At Kingston Compositions and methods for treating atherosclerosis
CA2533873A1 (en) * 2003-07-28 2005-04-07 David K.R. Karaolis Method for attenuating virulence of microbial pathogens and for inhibiting microbial biofilm formation
US7749509B2 (en) * 2003-08-29 2010-07-06 Cobb And Company, Llp Treatment of autism using probiotic composition
US7731976B2 (en) * 2003-08-29 2010-06-08 Cobb And Company, Llp Treatment of irritable bowel syndrome using probiotic composition
US20060177424A1 (en) * 2003-08-29 2006-08-10 Cobb Mark L Treatment of disease states and adverse physiological conditions utilizing anti-fungal compositions
US7759105B2 (en) * 2003-08-29 2010-07-20 Cobb & Company, Llp Probiotic composition useful for dietary augmentation and/or combating disease states and adverse physiological conditions
US8685374B2 (en) * 2003-09-12 2014-04-01 Ray And Terry's Health Products, Inc. EDTA containing compositions and uses thereof
US20060083727A1 (en) * 2004-07-15 2006-04-20 Nanobac Pharmaceuticals, Inc. Methods and compositions for the treatment of diseases characterized by calcification and/or plaque formation
US7691418B2 (en) * 2004-09-17 2010-04-06 Oystershell Nv Composition for inhibiting or preventing the formation of a biofilm
US9023323B2 (en) * 2004-12-16 2015-05-05 Colgate-Palmolive Company Oral compositions for prevention and reduction of bacterial adhesion to oral surfaces
US20060140881A1 (en) * 2004-12-22 2006-06-29 Guofeng Xu Oral care compositions containing flavonoids and flavans
EP1890708A4 (en) * 2005-06-01 2009-07-15 Biotec Inst For Internat GLUCOSE INDUCIBLE INSULIN EXPRESSION AND METHODS OF TREATING DIABETES
US8512724B2 (en) * 2005-06-10 2013-08-20 The Board Of Regents Of The University Of Texas System Antiseptic compositions
DE102005049649A1 (de) * 2005-10-18 2007-04-19 Pro Natura Gesellschaft für gesunde Ernährung mbH Zusammensetzung zur Linderung von Beschwerden des Magen-Darm-Trakts
WO2008035371A2 (en) * 2006-07-11 2008-03-27 Advanced Enzyme Technologies Limited Dietary anti-bacterial compositions
US20080019956A1 (en) * 2006-07-24 2008-01-24 Manoj Kumar Enzymatic prevention and control of biofilm
WO2011063394A2 (en) * 2009-11-23 2011-05-26 Olmstead Stephen F Compositions and methods comprising serratia peptidase for inhibition and treatment of biofilms related to certain conditions

Also Published As

Publication number Publication date
US20180258460A1 (en) 2018-09-13
US11078516B2 (en) 2021-08-03
WO2009100456A3 (en) 2009-12-03
JP6244291B2 (ja) 2017-12-06
JP6047273B2 (ja) 2016-12-21
NO2254591T3 (da) 2017-12-23
US20210332409A1 (en) 2021-10-28
ES2645062T3 (es) 2017-12-04
PT2254591T (pt) 2017-11-10
JP2015110559A (ja) 2015-06-18
EP2254591B1 (en) 2017-07-26
EP2254591A4 (en) 2012-09-12
PL2254591T3 (pl) 2018-01-31
US20090202516A1 (en) 2009-08-13
JP2011511809A (ja) 2011-04-14
CA2715266A1 (en) 2009-08-13
EP2254591A2 (en) 2010-12-01
WO2009100456A2 (en) 2009-08-13

Similar Documents

Publication Publication Date Title
DK2254591T3 (da) Inhibering eller behandling af gastrointestinal biofilm
DK2982696T3 (da) Behandling af akut lymfoblastær leukæmi
DK2350116T3 (da) Behandling af biofilm
NL300938I2 (nl) Niraparib tosylaat of niraparib tosylaat monohydraat
DK1986633T3 (da) Behandling af duchennes muskeldystrofi
DK2254598T3 (da) Kombination af alfa 7-nikotinagonister og antipsykotika
DK2111555T3 (da) Diagnosticering af præeklampsi
DK2300560T3 (da) Termisk behandling af biomasse
DK2395991T3 (da) Anvendelse af eicosapentaensyreethylester til behandling af hypertriglyceridæmi
DK2498771T3 (da) Anvendelse af bethanechol til behandling af xerostomi
EP2310144A4 (en) COATINGS
SI3354276T1 (sl) Sestavki za zdravljenje gastrointestinalnega vnetja
DK2373927T3 (da) Behandling af forbrændingsgas fra affaldsbehandling
DK3208269T3 (da) Inhibitorer af c-fms-kinase
DK2358714T3 (da) Alkylcyclohexylethere af dihydrotetraazabenzoazulener
DK2293816T3 (da) Fremgangsmåder til behandling af reumatoid arthritis
DK2421537T3 (da) Pyrazolylaminopyridiner som inhibitorer af FAK
DK2349310T3 (da) Polypeptid til behandling eller forebyggelse af adhæsioner
DK2403512T3 (da) Sammensætninger af polymer myrcen
IT1391986B1 (it) Ciabatta di tipo perfezionato
DK2459129T3 (da) Forbedringer af karstøtteanordninger
DK2252317T3 (da) Behandling af makuladegeneration
DK3284820T3 (da) Fremgangsmåde til behandling af pyropheophytin-holdige sammensætninger
BRPI0907954A2 (pt) Tratamento de hipertensão com 25-hidroxivitamina d3
DK2506840T3 (da) Anvendelser af hæmmere af hypoksi-fremkaldende faktorer